By Sabela Ojea


Takeda Pharmaceutical said the European Commission approved Fruzaqla to treat patients metastatic colorectal cancer.

The pharmaceutical company on Friday said the approval is aimed at patients who have been previously treated with available standard therapies and are intolerant to either trifluridine-tipiracil or regorafenib.

Fruzaqla is an oral, chemotherapy-free targeted agent.

The European Commission pass follows a recent positive opinion from the Committee for Medicinal Products for Human Use and a November 2023 approval by the U.S. Food and Drug Administration for metastatic colorectal cancer who have been previously treated with oxaliplatin and irinotecan-based regimens.

"For the first time in over a decade, patients with previously treated metastatic colorectal cancer have a new targeted treatment option that can be used irrespective of whether their tumors harbor actionable mutations," said Teresa Bitetti, president of Takeda's global oncology business unit.


Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix


(END) Dow Jones Newswires

06-21-24 1642ET